These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 32759365)

  • 1. Human Amyloid-β
    Peng HB; Noh K; Pan SR; Saldivia V; Serson S; Toscan A; de Lannoy IAM; Pang KS
    Drug Metab Dispos; 2020 Oct; 48(10):944-955. PubMed ID: 32759365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier.
    Fujiyoshi M; Tachikawa M; Ohtsuki S; Ito S; Uchida Y; Akanuma S; Kamiie J; Hashimoto T; Hosoya K; Iwatsubo T; Terasaki T
    J Neurochem; 2011 Aug; 118(3):407-15. PubMed ID: 21585370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein: a role in the export of amyloid-β in Alzheimer's disease?
    Chai AB; Leung GKF; Callaghan R; Gelissen IC
    FEBS J; 2020 Feb; 287(4):612-625. PubMed ID: 31750987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of degradation and brain-to-blood elimination across the blood-brain barrier to cerebral clearance of human amyloid-β peptide(1-40) in mouse brain.
    Ito S; Matsumiya K; Ohtsuki S; Kamiie J; Terasaki T
    J Cereb Blood Flow Metab; 2013 Nov; 33(11):1770-7. PubMed ID: 23963369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier.
    Ito S; Ohtsuki S; Terasaki T
    Neurosci Res; 2006 Nov; 56(3):246-52. PubMed ID: 16926058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability.
    Strazielle N; Ghersi-Egea JF; Ghiso J; Dehouck MP; Frangione B; Patlak C; Fenstermacher J; Gorevic P
    J Neuropathol Exp Neurol; 2000 Jan; 59(1):29-38. PubMed ID: 10744033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide.
    Sáez-Valero J; de Ceballos ML; Small DH; de Felipe C
    Neurosci Lett; 2002 Jun; 325(3):199-202. PubMed ID: 12044655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.
    Mackic JB; Bading J; Ghiso J; Walker L; Wisniewski T; Frangione B; Zlokovic BV
    Vascul Pharmacol; 2002 Jun; 38(6):303-13. PubMed ID: 12529925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
    Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
    Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid β -Peptide from the Brain.
    Wang W; Bodles-Brakhop AM; Barger SW
    Curr Alzheimer Res; 2016; 13(6):615-20. PubMed ID: 26971931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.
    Saito Y; Buciak J; Yang J; Pardridge WM
    Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10227-31. PubMed ID: 7479757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.
    Pan W; Solomon B; Maness LM; Kastin AJ
    Exp Biol Med (Maywood); 2002 Sep; 227(8):609-15. PubMed ID: 12192102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent inverse correlations in CSF and plasma amyloid-β(1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice.
    Cho SM; Lee S; Yang SH; Kim HY; Lee MJ; Kim HV; Kim J; Baek S; Yun J; Kim D; Kim YK; Cho Y; Woo J; Kim TS; Kim Y
    Sci Rep; 2016 Feb; 6():20185. PubMed ID: 26830653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active clearance of human amyloid beta 1-42 peptide aggregates from the rat ventricular system.
    Nakagawa Y; Yuzuriha T; Iwaki T
    Neuropathology; 2004 Sep; 24(3):194-200. PubMed ID: 15484697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.
    Zhou ZW; Chen X; Liang J; Yu XY; Wen JY; Zhou SF
    Drug Metab Lett; 2007 Aug; 1(3):205-17. PubMed ID: 19356045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.